TABLE 2.
Human hematopoietic cell lines release FeLV-B virions with markedly different specific infectivities
| Cell line | Origina | Level of virion releaseb | FeLV titer (FFU/ml)c |
|---|---|---|---|
| HEK293 | Human embryonic kidney cells | High | 105–106 |
| AH927 | Immortalized feline fibroblasts | High | 4 × 105 |
| HT1080 | Fibrosarcoma | High | 4 × 105 |
| KYO-1 | CML (blast crisis), t(9;22) | High | 3 × 103 |
| CEM | T-cell acute lymphoblastic leukemia | High | 4 × 104 |
| CEMSS | T-cell acute lymphoblastic leukemia | High | 6 × 104 |
| Jurkat | T-cell acute lymphoblastic leukemia | High | 4 × 102 |
| K562 | Erythroleukemia (CML blast crisis), t(9;22) | High | 103 |
| Kasumi | Acute myeloblastic leukemia | High | 3.5 × 102 |
| LAMA84 | Basophilic (CML blast crisis), t(9;22) | High | 1.3 × 101 |
| Raji | B-cell (Burkitt lymphoma), t(8;14) | High | 3 × 101 |
| TOM-1 | B-cell acute lymphocytic leukemia, t(9;22) | High | 1.6 ×101 |
| KU812 | Basophilic/erythroleukemia (CML blast crisis), t(9;22) | High | 2.3 × 103 |
| Reh | Pre-B-cell acute lymphocytic leukemia, t(12;21) | Low | 2 × 100 |
| bv173 | Undifferentiated blast, t(9;22) | Low | 2 |
| ALL/MIK | Pre-B-cell acute leukemia, t(9;22) | Low/negative | 5 × 101 |
| EM2 | Myeloblast (CML), t(9;22) | Low/negative | 2 |
| KG-1 | Acute myelogenous leukemia (M1) | Low/negative | 0 |
| PBMC (n = 4) | Normal peripheral blood monocytic cells | Negative | 0 |
| LCL (n = 4) | EBV-immortalized B-lymphoblastoid cell lines | Low | 0 |
a
CML, chronic myeloid leukemia.
b
Measured at 14 days after infection with FeLV-B at an MOI of 1 (Fig. 2C).
c
Infectious FeLV titer measured on QN10 (S+ L−) cells. FFU, focus-forming units.